Serotonin pharmacology in the gastrointestinal tract: a review

被引：87

作者：

Beattie, D. T. ^{[1
,2
]}

Smith, J. A. M. ^{[1
,2
]}

机构：

[1] Theravance Inc, Dept Pharmacol, San Francisco, CA 94080 USA

[2] Theravance Inc, Dept Mol & Cellular Biol, San Francisco, CA 94080 USA

来源：

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 2008年 / 377卷 / 03期

关键词：

5-HT; gastrointestinal; enteric nervous system;

D O I：

10.1007/s00210-008-0276-9

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Serotonin (5-hydroxytryptamine or 5-HT) plays a critical physiological role in the regulation of gastrointestinal (GI) function. 5-HT dysfunction may also be involved in the pathophysiology of a number of functional GI disorders, such as chronic constipation, irritable bowel syndrome and functional dyspepsia. This article describes the role of 5-HT in the enteric nervous system (ENS) of the mammalian GI tract and the receptors with which it interacts. Existing serotonergic therapies that have proven effective in the treatment of GI functional disorders and the potential of drugs currently in development are also highlighted. Advances in our understanding of the physiological and pathophysiological roles of 5-HT in the ENS and the identification of selective receptor ligands bodes well for the future development of more efficacious therapies for patients with functional GI disorders.

引用

页码：181 / 203

页数：23

共 297 条

[1] 5-HT3-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment [J].

Aapro, M .

ONCOLOGY, 2005, 69 (02) :97-109

[2] LONG-TERM EFFICACY OF ORAL CISAPRIDE IN SYMPTOMATIC UPPER GUT DYSMOTILITY [J].

ABELL, TL ;

CAMILLERI, M ;

DIMAGNO, EP ;

HENCH, VS ;

ZINSMEISTER, AR ;

MALAGELADA, JR .

DIGESTIVE DISEASES AND SCIENCES, 1991, 36 (05) :616-620

[3] CLONING OF ANOTHER HUMAN SEROTONIN RECEPTOR (5-HT1F) - A 5TH 5-HT1 RECEPTOR SUBTYPE COUPLED TO THE INHIBITION OF ADENYLATE-CYCLASE [J].

ADHAM, N ;

KAO, HT ;

SCHECHTER, LE ;

BARD, J ;

OLSEN, M ;

URQUHART, D ;

DURKIN, M ;

HARTIG, PR ;

WEINSHANK, RL ;

BRANCHEK, TA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (02) :408-412

[4]

ALEXANDER SPH, 2004, BR J PHARM SUPPL, V141, pS36

[5] COMPARATIVE EFFICACY OF A SINGLE ORAL DOSE OF ONDANSETRON AND OF BUSPIRONE AGAINST CISPLATIN-INDUCED EMESIS IN CANCER-PATIENTS [J].

ALFIERI, AB ;

CUBEDDU, LX .

BRITISH JOURNAL OF CANCER, 1995, 72 (04) :1013-1015

[6]

*AM GASTR ASS, 2002, BURD GASTR DIS

[7] Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome [J].

Atkinson, W ;

Lockhart, S ;

Whorwell, PJ ;

Keevil, B ;

Houghton, LA .

GASTROENTEROLOGY, 2006, 130 (01) :34-43

[8]

Bacon WL, 2000, J PHARMACOL EXP THER, V294, P672

[9] Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor [J].

Bai, F ;

Yin, TG ;

Johnstone, EM ;

Su, C ;

Varga, G ;

Little, SP ;

Nelson, DL .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 484 (2-3) :127-139

[10] Rationale for using serotonergic agents to treat irritable bowel syndrome [J].

Baker, DE .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (07) :700-711

← 1 2 3 4 5 6 7 8 9 10 →